10-Q: Pulse Biosciences Q2 2026: Focus on Cardiac, Cash Burn Continues

Pulse Biosciences, Inc. reported its Q2 2026 results, highlighting progress in cardiac device development while continuing to incur significant operating losses and relying on equity financing.

Summary

• Pulse Biosciences, Inc. filed its Form 10-Q for the quarter ended June 30, 2026.
• The company reported a net loss of $24.7 million for the three months ended June 30, 2026, compared to a net loss of $19.2 million for the same period in 2025.
• For the six months ended June 30, 2026, the net loss was $43.2 million, compared to $36.0 million for the same period in 2025.
• Cash and cash equivalents stood at $101.6 million as of June 30, 2026.
• The company continues to focus on the development of its Nano-pulse Stimulation (NPS) technology, particularly for atrial fibrillation (AF) treatment.
• Product revenue for the three months ended June 30, 2026, was $0.4 million, with no revenue reported for the prior year's comparable period.
• Research and development expenses increased significantly, driven by clinical trials and compensation costs.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the continued net losses, significant cash burn, and the inherent risks associated with medical device development and commercialization, despite progress in key areas.

Positives

• Generated $0.4 million in product revenue from the Vybrance Percutaneous Electrode System during the three months ended June 30, 2026, a new revenue stream compared to the prior year.
• Secured $46.8 million in net proceeds from an at-the-market (ATM) offering program in the first half of 2026.
• Continued progress in clinical studies for the nPulse Cardiac Catheter System, with 96% procedural success reported at one year for a cohort of patients.
• Received FDA Breakthrough Device Designation for the nPulse Cardiac Surgery System for AF treatment.
• The company believes its existing financial resources are sufficient to fund operations for at least one year past the issuance date of the financial statements.

Negatives

• Reported a net loss of $24.7 million for the three months ended June 30, 2026, an increase from $19.2 million in the prior year.
• Net loss for the six months ended June 30, 2026, was $43.2 million, an increase from $35.9 million in the prior year.
• Significant increase in Research and Development expenses, up $4.9 million for the quarter and $7.2 million for the six-month period, primarily due to clinical trials and compensation.
• Interest income decreased significantly due to lower cash equivalents and decreasing yield rates.
• The company has a history of net operating losses and negative cash flows from operations since inception, with an accumulated deficit of $506.5 million as of June 30, 2026.

Risks

• The company will need to obtain additional funding to finance operations and product commercialization, which may result in dilution or increased indebtedness.
• Failure to successfully develop and commercialize its patented NPS technology could lead to extended financial losses.
• Medical device development and commercialization is complex, time-consuming, and expensive, with a high rate of failure.
• There is no assurance that clinical product candidates will obtain regulatory approval or that clinical study results will be favorable.
• The company faces substantial competition from well-established incumbent technologies and companies with greater financial and technical resources.
• Reliance on a single platform technology (NPS) and product family creates significant risk.
• The company's ability to commercialize products is subject to substantial regulatory and legislative uncertainty, including pricing and reimbursement.
• The company is subject to stringent domestic and foreign regulations, and unfavorable regulatory action could materially affect its business.

Future Outlook

The company believes its existing financial resources are sufficient to continue operating activities for at least one year past the issuance date of these condensed consolidated financial statements. However, it plans to raise additional capital in the near future. The company expects to continue to incur additional losses for the next several years due to ongoing investments in research and development and market development.

Management Comments

• Stock-based compensation expense for stock awards with performance-based vesting conditions is not recognized until it is probable that the performance-based vesting condition will be achieved.
• The Company believes that the existing financial resources are sufficient to continue operating activities for at least one year past the issuance date of these condensed consolidated financial statements.
• We believe nsPFA energy is uniquely suited to perform an integral role in the treatment of AF and that it will prove to be highly differentiated from other energy modalities in use today.
• We believe nsPFA technology, which delivers pulses of electrical energy that are each less than a millionth of a second long, can offer similar safety advantages as PFA and may provide improved efficacy advantages based on the circumferential design of our catheter and because it appears nsPFA technology can create deeper ablations.

Industry Context

StockSavvy.ai notes that Pulse Biosciences operates in the highly competitive and rapidly evolving medical device sector, specifically focusing on ablation technologies. The company's strategic shift towards atrial fibrillation (AF) treatment aligns with a significant market opportunity, but also places it in direct competition with established players and emerging pulsed field ablation (PFA) technologies.

Comparison to Industry Standards

• The company's nPulse Cardiac Catheter System aims for circumferential ablation in a single cycle, potentially offering faster treatment times than current thermal modalities, a key differentiator in the AF treatment market.
• While other PFA technologies exist, Pulse Biosciences emphasizes its nsPFA technology's unique pulse width and potential for deeper ablations, aiming for differentiation against micro-PFA devices that have rapidly gained market share.
• The Vybrance Percutaneous Electrode System for thyroid nodules faces competition from established surgical procedures and thermal ablation technologies like RFA and MWA, which have longer clinical track records and established reimbursement pathways.
• The company's reliance on equity financing and its significant accumulated deficit are common among early-stage medical device companies, but highlight the need for successful product commercialization and market adoption to achieve profitability.

Legal Proceedings

• The company is not presently a party to any legal proceedings that, in the opinion of management, could have a material adverse effect on its results of operations or financial condition.

Related Party Transactions

• Robert W. Duggan, majority stockholder and Co-Chairman, and Paul LaViolette, CEO and Co-Chairman, indicated intent to purchase shares at prevailing market prices under the February 2026 ATM.
• Mr. Duggan and Mr. LaViolette purchased 675,233 shares of common stock in aggregate under the February 2026 ATM during the three and six months ended June 30, 2026.
• Robert W. Duggan purchased approximately 88% of the units offered through the 2024 Rights Offering.

Stakeholder Impact

• Shareholders may experience dilution due to ongoing equity financing efforts.
• Investors face continued risk due to the company's net losses and reliance on future financing.
• Patients may benefit from the development of novel treatments for atrial fibrillation and other conditions.
• Healthcare providers may adopt new technologies if clinical efficacy, safety, and reimbursement are established.

Next Steps

• Prioritize and accelerate the development of nsPFA electrophysiology catheters and other cardiac devices for the treatment of atrial fibrillation.
• Reduce short-term market development investments in cardiac surgery and sales/marketing for the Vybrance Percutaneous Electrode System.
• Generate clinical data for expanded reimbursement coverage and regulatory label claims.
• Pursue PMA approval from the FDA for the nPulse Cardiac Catheter System for AF treatment in the United States.
• Commercialize the nPulse Cardiac Catheter System in the United States, potentially through strategic partnerships.
• Pursue a PMA application for FDA approval to market the cardiac clamp specifically as a surgical way to treat both paroxysmal and persistent AF.
• Continue to pursue commercialization of the Vybrance System in the United States, supported by the PRECISE BTN clinical trial.
• Continue to explore partnership opportunities for additional applications of NPS technology.

Key Dates

Recommendation

The company shows promising technological development in a significant market (AF treatment), but faces substantial financial risks, ongoing losses, and intense competition. While recent product revenue is a positive step, the path to profitability is long and uncertain, warranting a hold position until further clinical and commercial milestones are achieved and financing risks are better understood.

Keywords

medical device, atrial fibrillation, cardiac ablation, NPS technology, nsPFA, clinical trials, FDA approval, startup